Caribou falls after scrapping cell therapy programs, launches strategic review
CRBU•Caribou Biosciences shares fell 36.1% to $0.73 in extended trading after the company said it would discontinue two experimental cell therapies and explore a potential sale, merger or other options. It reported $113.8 million in cash, cash equivalents and marketable securities as of June 30, 2026.
1. Programs discontinued
Caribou plans to stop developing vispa-cel for a type of blood cancer and CB-011 for multiple myeloma, and is exploring a potential sale, merger or other options to unlock shareholder value. The company said challenging funding conditions for allogeneic CAR-T therapies made it difficult to secure capital to advance the programs; it also plans workforce and cost cuts.
